EMA OST-HER2 coverage for business development, investment, and market access teams
Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
OS Therapies' OST-HER2 Trial Hits 2.5-Year Survival Milestone in Osteosarcoma
OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress
OS Therapies Acquires Full IP Rights to OST-HER2 for $8M